Browse drugs

…ceive either monotherapy doublet or triple combination therapy. Puxi-sam was administered as a single i.v. dose at 7 mg/kg, saruparib wa…

…hibition and ADCC to be achieved by one modality. Our lead mAb, WBMP-4, binds to membrane-bound IgM, within the B-cell Receptor (BCR),…

…s Our results showed that the intraperitoneal administration of artLCMV-NanoLuc achieved sustained transgene expression in the peritoneal cavit…

…, Nelson K, Proclivo VH, McGuire KL, Giacalone MJ. Intravesical VAX014 synergizes with PD-L1 blockade to enhance local and systemic co…

…dscape of ER+ BC. By converting ‘cold’ tumours into ‘hot’ ones, VacV000 holds promise for synergistic use with other immunotherapies.Ac…

… diminished functional heterogeneity of intra-tumoral NK cells. B10G5 treatment enriched a TCF1-hi stem-like NK reservoir and thereby…

… injection of either human PBMC or purified T cells followed by HCW11-018b (1mg/kg, s.c.) the following day. Treatments were administered …

…Background T cell engagers (TCEs) are clinically successful bispecific antibodies, albeit primar…

…of DC and CD4+ T cells were also identified at various doses of hAbC (figure 2). Co-culture of DCs and CD4+ T cells lead to modulati…

…ivo, thereby validating these CD3 VHHs as an ideal platform for TCE engineering.…

…tion of anti-apoptotic markers in T cells. In xenograft models, TriAb significantly inhibited tumor growth, enhanced T cell prolifera…

…multiplier adjustments to improve clinical utility. Adoption of AADD with a ×11 multiplier could enhance cost-effectiveness and pati…